Tag: DAPT

TCT 2026: Reduced-dose NOACs and aspirin non-inferior to DAPT for six-month...

Boston Scientific has announced positive six-month primary endpoint results from the SIMPLAAFY randomised controlled trial of the Watchman FLX Pro left atrial appendage closure...

ESC 2017: Case builds for dropping aspirin from triple therapy in...

The RE-DUAL PCI trial indicates that dual therapy with the non-vitamin K antagonist oral anticoagulant dabigatran (Pradaxa, Boehringer Ingelheim)—and not aspirin—and a P2Y12 inhibitor...